Admera Health, a South Plainfield, NJ-based molecular diagnostics company focused on personalized medicine, completed a Series A round of financing of undisclosed amount.
The round was led by Prime Value Capital Management (PVCM) with participation from Sungent Bioventure. In conjunction with the funding, PVCM’s founding partner, Dr. Chenhui Wen, will join Admera Health’s Board of Directors.
The company intends to use the funds to expand operations and accelerate the product development.
Led by Dr. Guanghui Hu, President, Admera Health currently markets products focused on personalized medicine and non-invasive cancer testing, including PGxOne™ Plus and OncoGxOne™, both of which apply sequencing and advanced bioinformatics analysis. PGxOne™ Plus is an expanded version of PGxOne™, a proprietary pharmacogenomics test that helps predict patient responses to drug therapy based on individual genetic makeup. OncoGxOne™ detects all currently known, clinically relevant genetic alterations in cancer genes and provides medically actionable recommendations for targeted therapy and chemotherapy.
Admera Health is a GENEWIZ company.